Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 512625

Biologic immunotherapy in psoriasis


Prpić-Massari, Larisa; Kaštelan, Marija; Simonić, Edita; Brajac, Ines; Peternel, Sandra
Biologic immunotherapy in psoriasis // 4th Congress of Croatian Dermatovenereologists with International Participation - Abstract Book.
Osijek, Hrvatska, 2011. (predavanje, međunarodna recenzija, sažetak, stručni)


CROSBI ID: 512625 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Biologic immunotherapy in psoriasis

Autori
Prpić-Massari, Larisa ; Kaštelan, Marija ; Simonić, Edita ; Brajac, Ines ; Peternel, Sandra

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni

Izvornik
4th Congress of Croatian Dermatovenereologists with International Participation - Abstract Book. / - , 2011

Skup
4. Kongres hrvatskih dermatovenerologa s međunarodnim sudjelovanjem

Mjesto i datum
Osijek, Hrvatska, 05.-08.05.2011

Vrsta sudjelovanja
Predavanje

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
Psoriasis; Biologic immunotherapy; Infliximab; Adalimumab; Etanercept; Ustekinumab

Sažetak
Psoriasis is generally considered as T cell mediated autoimmune disease. Recent studies in the pathogenesis of psoriasis has shown that upon triggering T lymphocytes secrete cytokines, chemokines and growth factors and consequently initiate keratinocyte proliferation. Besides traditionally immunomodulatory agents used in treatment of severe-to- moderate psoriasis such as photochemotherapy, methotrexate, cyclosporine and retinoids, new immunomodulatory therapy lately appeared. Those agents called biologic response modifiers or simply biologics act by targeting the precise elements in immunological cascade. Therefore, they can be classified into three categories: T-cell modulating agents (eg. alefacept and efalizumab), the inhibitors of tumor necrosis factor- alpha (TNF- alpha) (eg. adalimumab, etanercept, infliximab) and the inhibitors of interleukin (IL)-12 and IL-23 (eg. ustekinumab). Herein, we give a brief overwiev of action of those agents as well as present our experience in using these agents in therapy of psoriasis.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA


Projekti:
062-0620239-0197 - Imunološki mehanizmi u patogenezi psorijaze (Kaštelan, Marija, MZOS ) ( POIROT)
062-0620239-0199 - Uloga neurogene upale i psihičkih čimbenika u patogenezi psorijaze (Brajac, Ines, MZOS ) ( POIROT)

Ustanove:
Medicinski fakultet, Rijeka,
Klinički bolnički centar Rijeka


Citiraj ovu publikaciju:

Prpić-Massari, Larisa; Kaštelan, Marija; Simonić, Edita; Brajac, Ines; Peternel, Sandra
Biologic immunotherapy in psoriasis // 4th Congress of Croatian Dermatovenereologists with International Participation - Abstract Book.
Osijek, Hrvatska, 2011. (predavanje, međunarodna recenzija, sažetak, stručni)
Prpić-Massari, L., Kaštelan, M., Simonić, E., Brajac, I. & Peternel, S. (2011) Biologic immunotherapy in psoriasis. U: 4th Congress of Croatian Dermatovenereologists with International Participation - Abstract Book..
@article{article, year = {2011}, keywords = {Psoriasis, Biologic immunotherapy, Infliximab, Adalimumab, Etanercept, Ustekinumab}, title = {Biologic immunotherapy in psoriasis}, keyword = {Psoriasis, Biologic immunotherapy, Infliximab, Adalimumab, Etanercept, Ustekinumab}, publisherplace = {Osijek, Hrvatska} }
@article{article, year = {2011}, keywords = {Psoriasis, Biologic immunotherapy, Infliximab, Adalimumab, Etanercept, Ustekinumab}, title = {Biologic immunotherapy in psoriasis}, keyword = {Psoriasis, Biologic immunotherapy, Infliximab, Adalimumab, Etanercept, Ustekinumab}, publisherplace = {Osijek, Hrvatska} }




Contrast
Increase Font
Decrease Font
Dyslexic Font